Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings

BACKGROUND: Hereditary angioedema (HAE) is a rare genetic disease causing unpredictable and potentially life-threatening subcutaneous and submucosal edematous attacks. Cinryze® (Shire ViroPharma Inc., Lexington, MA, USA), a nanofiltered C1 inhibitor (C1-INH), is approved in Europe for the treatment,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Int Arch Allergy Immunol
Autores principales: Aygören-Pürsün, Emel, Soteres, Daniel, Moldovan, Dumitru, Christensen, Jim, Van Leerberghe, Arthur, Hao, James, Schranz, Jennifer, Jacobson, Kraig W., Martinez-Saguer, Inmaculada
Formato: Artigo
Lenguaje:Inglês
Publicado: S. Karger AG 2017
Materias:
Basic and Clinical Immunology - Short Communication
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5841133/
https://ncbi.nlm.nih.gov/pubmed/28662509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000477541
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares